Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Two-Stage, Comparative Pharmacokinetic Study of EirGenix' Trastuzumab and Herceptin® (Trastuzumab) Sourced From US and EU Administered to Healthy Male Volunteers

NCT03180242 is registered in ClinicalTrials.gov with EirGenix, Inc. as lead sponsor.

NCT NCT03180242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03180242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Two-Stage, Comparative Pharmacokinetic Study of EirGenix' Trastuzumab and Herceptin® (Trastuzumab) Sourced From US and EU Administered to Healthy Male Volunteers
Lead sponsor
EirGenix, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 22, 2016
Completion date
August 22, 2016
Enrollment
84 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy